Can immune cells from belly fluid fight advanced cancer?
NCT ID NCT07378436
First seen Jan 31, 2026 · Last updated Jun 19, 2026 · Updated 24 times
Summary
This early-phase trial tests a new treatment called GK02 for people with advanced solid tumors that cause fluid buildup in the belly (malignant ascites). The treatment uses the patient's own immune cells taken from that fluid, grown in a lab, and then given back. Only 9 participants will be enrolled to check safety and see if it helps control the fluid or the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT ASCITES CAUSED BY ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tumor-reactive T cells (GK02) taken from the patient's own ascites fluid
What this could lead to
If it works, this could point toward a new way to control malignant ascites and slow tumor growth in advanced cancers.
What could go wrong
This is a very early, tiny trial (9 people) focused on safety. The treatment may not shrink tumors or improve survival, and side effects could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.